Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Erica M, Gomes"'
Autor:
Alex W. Tong, Marvin J. Stone, Joseph Newman, Joe Kansopon, Dongkun Chang, Reuben Hernandez-Alcoceba, Lindsay D. Butcher, Erica M. Gomes, Margret S. Fernandes
Supplementary Data from Growth Inhibition of Human Multiple Myeloma Cells by an Oncolytic Adenovirus Carrying the CD40 Ligand Transgene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4725954a492ce6a0fd9260c3b7d9e66e
https://doi.org/10.1158/1078-0432.22440796.v1
https://doi.org/10.1158/1078-0432.22440796.v1
Autor:
Richard P. Junghans, Rosa M. Gonzalo-Daganzo, David L. Liu, Erica M. Gomes, Agnes S.Y. Lo, Peter C.R. Emtage
Purpose: This report describes the development and preclinical qualification tests of second-generation anti-carcinoembryonic (CEA) designer T cells for use in human trials.Experimental Design: The progenitor first-generation immunoglobulin-T-cell re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::609f06263a3fd6e3e52001c2a003e799
https://doi.org/10.1158/1078-0432.c.6517050
https://doi.org/10.1158/1078-0432.c.6517050
Autor:
Richard P. Junghans, Rosa M. Gonzalo-Daganzo, David L. Liu, Erica M. Gomes, Agnes S.Y. Lo, Peter C.R. Emtage
Supplementary Data from Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630a40d59c3a5498dfe3137da91c74a5
https://doi.org/10.1158/1078-0432.22439610.v1
https://doi.org/10.1158/1078-0432.22439610.v1
Autor:
Alex W. Tong, Marvin J. Stone, Joseph Newman, Joe Kansopon, Dongkun Chang, Reuben Hernandez-Alcoceba, Lindsay D. Butcher, Erica M. Gomes, Margret S. Fernandes
Purpose: The growth-inhibitory activity of recombinant CD40 ligand (CD40L) is well documented in human multiple myeloma (MM). We examined MM-targeted delivery of CD40L by a conditional replicative oncolytic adenovirus, AdEHCD40L.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e57faa45f585d750bb8a95ceda141f6
https://doi.org/10.1158/1078-0432.c.6518071
https://doi.org/10.1158/1078-0432.c.6518071
Autor:
Hongliang Zong, Alexander Gozman, Eloisi Caldas-Lopes, Tony Taldone, Eric Sturgill, Sarah Brennan, Stefan O. Ochiana, Erica M. Gomes-DaGama, Siddhartha Sen, Anna Rodina, John Koren III, Michael W. Becker, Charles M. Rudin, Ari Melnick, Ross L. Levine, Gail J. Roboz, Stephen D. Nimer, Gabriela Chiosis, Monica L. Guzman
Publikováno v:
Cell Reports, Vol 13, Iss 10, Pp 2159-2173 (2015)
Acute myeloid leukemia (AML) is a heterogeneous and fatal disease with an urgent need for improved therapeutic regimens given that most patients die from relapsed disease. Irrespective of mutation status, the development of aggressive leukemias is en
Externí odkaz:
https://doaj.org/article/03d9a17749844c7d85caa19fad88d006
Autor:
Anthony Bais, Qiangzhong Ma, Stephen I. Cohen, A. Samer Al-Homsi, Erica M. Gomes, Howard Cabral, Mehrdad Abedi, Richard P. Junghans, Ritesh Rathore, Robin Davies, Agnes Lo
Publikováno v:
The Prostate. 76:1257-1270
BACKGROUND Chimeric antigen receptor (CAR)-modified “designer” T cells (dTc, CAR-T) against PSMA selectively target antigen-expressing cells in vitro and eliminate tumors in vivo. Interleukin 2 (IL2), widely used in adoptive therapies, was proven
Autor:
Siddhartha Sen, Tony Taldone, Sarah Brennan, Michael W. Becker, John Koren, Erica M. Gomes-DaGama, Stephen D. Nimer, Ross L. Levine, Hongliang Zong, Eloisi Caldas-Lopes, Gabriela Chiosis, Monica L. Guzman, Alexander Gozman, Charles M. Rudin, Anna Rodina, Gail J. Roboz, Ari Melnick, Eric M. Sturgill, Stefan O. Ochiana
Publikováno v:
Cell reports
Cell Reports, Vol 13, Iss 10, Pp 2159-2173 (2015)
Cell Reports, Vol 13, Iss 10, Pp 2159-2173 (2015)
SUMMARY Acute myeloid leukemia (AML) is a heterogeneous and fatal disease with an urgent need for improved therapeutic regimens given that most patients die from relapsed disease. Irrespective of mutation status, the development of aggressive leukemi
Publikováno v:
The Prostate. 74:286-296
BACKGROUND Adoptive immunotherapy by infusion of designer T cells (dTc) engineered with chimeric antigen receptors (CARs) for tumoricidal activity represents a potentially highly specific modality for the treatment of cancer. In this study, 2nd gener
Autor:
Richard P, Junghans, Qiangzhong, Ma, Ritesh, Rathore, Erica M, Gomes, Anthony J, Bais, Agnes S Y, Lo, Mehrdad, Abedi, Robin A, Davies, Howard J, Cabral, A Samer, Al-Homsi, Stephen I, Cohen
Publikováno v:
The Prostate. 76(14)
Chimeric antigen receptor (CAR)-modified "designer" T cells (dTc, CAR-T) against PSMA selectively target antigen-expressing cells in vitro and eliminate tumors in vivo. Interleukin 2 (IL2), widely used in adoptive therapies, was proven essential in a
Autor:
Reuben Hernandez-Alcoceba, Margret S. Fernandes, Lindsay D. Butcher, Dongkun Chang, Joe Kansopon, Marvin J. Stone, Alex W. Tong, Joseph T. Newman, Erica M. Gomes
Publikováno v:
Clinical Cancer Research. 15:4847-4856
Purpose: The growth-inhibitory activity of recombinant CD40 ligand (CD40L) is well documented in human multiple myeloma (MM). We examined MM-targeted delivery of CD40L by a conditional replicative oncolytic adenovirus, AdEHCD40L. Experimental Design: